Arcus Biosciences Stock Probability of Future Stock Price Finishing Over 15.55

RCUS Stock  USD 15.55  0.82  5.57%   
Arcus Biosciences' implied volatility is one of the determining factors in the pricing options written on Arcus Biosciences. Implied volatility approximates the future value of Arcus Biosciences based on the option's current value. Options with high implied volatility have higher premiums and can be used to hedge the downside of investing in Arcus Biosciences over a specific time period. For example, 2024-05-17 CALL at $15.0 is a CALL option contract on Arcus Biosciences' common stock with a strick price of 15.0 expiring on 2024-05-17. The contract was last traded on 2024-04-26 at 11:45:48 for $1.05 and, as of today, has 19 days remaining before the expiration. The option is currently trading at a bid price of $1.15, and an ask price of $1.55. The implied volatility as of the 28th of April is 72.12. View All Arcus options

Closest to current price Arcus long CALL Option Payoff at Expiration

Arcus Biosciences' future price is the expected price of Arcus Biosciences instrument. It is based on its current growth rate as well as the projected cash flow expected by the investors. This tool provides a mechanism to make assumptions about the upside potential and downside risk of Arcus Biosciences performance during a given time horizon utilizing its historical volatility. Check out Arcus Biosciences Backtesting, Arcus Biosciences Valuation, Arcus Biosciences Correlation, Arcus Biosciences Hype Analysis, Arcus Biosciences Volatility, Arcus Biosciences History as well as Arcus Biosciences Performance.
For more information on how to buy Arcus Stock please use our How to Invest in Arcus Biosciences guide.
  
At this time, Arcus Biosciences' Price Book Value Ratio is comparatively stable compared to the past year. Price To Book Ratio is likely to gain to 3.39 in 2024, despite the fact that Price Earnings Ratio is likely to grow to (4.37). Please specify Arcus Biosciences' target price for which you would like Arcus Biosciences odds to be computed.

Arcus Biosciences Target Price Odds to finish over 15.55

The tendency of Arcus Stock price to converge on an average value over time is a known aspect in finance that investors have used since the beginning of the stock market for forecasting. However, many studies suggest that some traded equity instruments are consistently mispriced before traders' demand and supply correct the spread. One possible conclusion to this anomaly is that these stocks have additional risk, for which investors demand compensation in the form of extra returns.
Current PriceHorizonTarget PriceOdds to move above the current price in 90 days
 15.55 90 days 15.55 
about 81.05
Based on a normal probability distribution, the odds of Arcus Biosciences to move above the current price in 90 days from now is about 81.05 (This Arcus Biosciences probability density function shows the probability of Arcus Stock to fall within a particular range of prices over 90 days) .
Given the investment horizon of 90 days the stock has the beta coefficient of 3.52 indicating as the benchmark fluctuates upward, the company is expected to outperform it on average. However, if the benchmark returns are projected to be negative, Arcus Biosciences will likely underperform. Additionally Arcus Biosciences has a negative alpha, implying that the risk taken by holding this instrument is not justified. The company is significantly underperforming the NYSE Composite.
   Arcus Biosciences Price Density   
       Price  

Predictive Modules for Arcus Biosciences

There are currently many different techniques concerning forecasting the market as a whole, as well as predicting future values of individual securities such as Arcus Biosciences. Regardless of method or technology, however, to accurately forecast the stock market is more a matter of luck rather than a particular technique. Nevertheless, trying to predict the stock market accurately is still an essential part of the overall investment decision process. Using different forecasting techniques and comparing the results might improve your chances of accuracy even though unexpected events may often change the market sentiment and impact your forecasting results.
Sophisticated investors, who have witnessed many market ups and downs, anticipate that the market will even out over time. This tendency of Arcus Biosciences' price to converge to an average value over time is called mean reversion. However, historically, high market prices usually discourage investors that believe in mean reversion to invest, while low prices are viewed as an opportunity to buy.
Hype
Prediction
LowEstimatedHigh
11.2215.6120.00
Details
Intrinsic
Valuation
LowRealHigh
14.0022.0126.40
Details
Naive
Forecast
LowNextHigh
9.8414.2318.62
Details
11 Analysts
Consensus
LowTargetHigh
39.2043.0847.82
Details
Please note, it is not enough to conduct a financial or market analysis of a single entity such as Arcus Biosciences. Your research has to be compared to or analyzed against Arcus Biosciences' peers to derive any actionable benefits. When done correctly, Arcus Biosciences' competitive analysis will give you plenty of quantitative and qualitative data to validate your investment decisions or develop an entirely new strategy toward taking a position in Arcus Biosciences.

Arcus Biosciences Risk Indicators

For the most part, the last 10-20 years have been a very volatile time for the stock market. Arcus Biosciences is not an exception. The market had few large corrections towards the Arcus Biosciences' value, including both sudden drops in prices as well as massive rallies. These swings have made and broken many portfolios. An investor can limit the violent swings in their portfolio by implementing a hedging strategy designed to limit downside losses. If you hold Arcus Biosciences, one way to have your portfolio be protected is to always look up for changing volatility and market elasticity of Arcus Biosciences within the framework of very fundamental risk indicators.
α
Alpha over NYSE Composite
-0.17
β
Beta against NYSE Composite3.52
σ
Overall volatility
1.58
Ir
Information ratio 0.01

Arcus Biosciences Alerts and Suggestions

In today's market, stock alerts give investors the competitive edge they need to time the market and increase returns. Checking the ongoing alerts of Arcus Biosciences for significant developments is a great way to find new opportunities for your next move. Suggestions and notifications for Arcus Biosciences can help investors quickly react to important events or material changes in technical or fundamental conditions and significant headlines that can affect investment decisions.
Arcus Biosciences had very high historical volatility over the last 90 days
The company reported the previous year's revenue of 117 M. Net Loss for the year was (307 M) with loss before overhead, payroll, taxes, and interest of (176 M).
Arcus Biosciences currently holds about 1.05 B in cash with (306 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 14.48.
Arcus Biosciences has a poor financial position based on the latest SEC disclosures
Roughly 60.0% of the company shares are owned by institutional investors
Latest headline from businesswire.com: Arcus Biosciences to Host Conference Call to Discuss First-Quarter 2024 Financial Results and Pipeline Update

Arcus Biosciences Price Density Drivers

Market volatility will typically increase when nervous long traders begin to feel the short-sellers pressure to drive the market lower. The future price of Arcus Stock often depends not only on the future outlook of the current and potential Arcus Biosciences' investors but also on the ongoing dynamics between investors with different trading styles. Because the market risk indicators may have small false signals, it is better to identify suitable times to hedge a portfolio using different long/short signals. Arcus Biosciences' indicators that are reflective of the short sentiment are summarized in the table below.
Common Stock Shares Outstanding74 M
Cash And Short Term Investments759 M

Arcus Biosciences Technical Analysis

Arcus Biosciences' future price can be derived by breaking down and analyzing its technical indicators over time. Arcus Stock technical analysis helps investors analyze different prices and returns patterns as well as diagnose historical swings to determine the real value of Arcus Biosciences. In general, you should focus on analyzing Arcus Stock price patterns and their correlations with different microeconomic environments and drivers.

Arcus Biosciences Predictive Forecast Models

Arcus Biosciences' time-series forecasting models is one of many Arcus Biosciences' stock analysis techniques aimed to predict future share value based on previously observed values. Time-series forecasting models are widely used for non-stationary data. Non-stationary data are called the data whose statistical properties, e.g., the mean and standard deviation, are not constant over time, but instead, these metrics vary over time. This non-stationary Arcus Biosciences' historical data is usually called time series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the stock market movement and maximize returns from investment trading.

Things to note about Arcus Biosciences

Checking the ongoing alerts about Arcus Biosciences for important developments is a great way to find new opportunities for your next move. Our stock alerts and notifications screener for Arcus Biosciences help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.
Arcus Biosciences had very high historical volatility over the last 90 days
The company reported the previous year's revenue of 117 M. Net Loss for the year was (307 M) with loss before overhead, payroll, taxes, and interest of (176 M).
Arcus Biosciences currently holds about 1.05 B in cash with (306 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 14.48.
Arcus Biosciences has a poor financial position based on the latest SEC disclosures
Roughly 60.0% of the company shares are owned by institutional investors
Latest headline from businesswire.com: Arcus Biosciences to Host Conference Call to Discuss First-Quarter 2024 Financial Results and Pipeline Update
When determining whether Arcus Biosciences is a strong investment it is important to analyze Arcus Biosciences' competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Arcus Biosciences' future performance. For an informed investment choice regarding Arcus Stock, refer to the following important reports:
Check out Arcus Biosciences Backtesting, Arcus Biosciences Valuation, Arcus Biosciences Correlation, Arcus Biosciences Hype Analysis, Arcus Biosciences Volatility, Arcus Biosciences History as well as Arcus Biosciences Performance.
For more information on how to buy Arcus Stock please use our How to Invest in Arcus Biosciences guide.
You can also try the Portfolio Suggestion module to get suggestions outside of your existing asset allocation including your own model portfolios.

Complementary Tools for Arcus Stock analysis

When running Arcus Biosciences' price analysis, check to measure Arcus Biosciences' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Arcus Biosciences is operating at the current time. Most of Arcus Biosciences' value examination focuses on studying past and present price action to predict the probability of Arcus Biosciences' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Arcus Biosciences' price. Additionally, you may evaluate how the addition of Arcus Biosciences to your portfolios can decrease your overall portfolio volatility.
Pattern Recognition
Use different Pattern Recognition models to time the market across multiple global exchanges
Positions Ratings
Determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance
Equity Analysis
Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities
Stocks Directory
Find actively traded stocks across global markets
Idea Optimizer
Use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio
Portfolio Holdings
Check your current holdings and cash postion to detemine if your portfolio needs rebalancing
Bollinger Bands
Use Bollinger Bands indicator to analyze target price for a given investing horizon
Money Flow Index
Determine momentum by analyzing Money Flow Index and other technical indicators
Bonds Directory
Find actively traded corporate debentures issued by US companies
Equity Forecasting
Use basic forecasting models to generate price predictions and determine price momentum
CEOs Directory
Screen CEOs from public companies around the world
Premium Stories
Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope
Is Arcus Biosciences' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Arcus Biosciences. If investors know Arcus will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Arcus Biosciences listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(4.15)
Revenue Per Share
1.581
Quarterly Revenue Growth
(0.09)
Return On Assets
(0.17)
Return On Equity
(0.55)
The market value of Arcus Biosciences is measured differently than its book value, which is the value of Arcus that is recorded on the company's balance sheet. Investors also form their own opinion of Arcus Biosciences' value that differs from its market value or its book value, called intrinsic value, which is Arcus Biosciences' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Arcus Biosciences' market value can be influenced by many factors that don't directly affect Arcus Biosciences' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Arcus Biosciences' value and its price as these two are different measures arrived at by different means. Investors typically determine if Arcus Biosciences is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Arcus Biosciences' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.